Taken together this evidence suggests important therapeutic and translational applications of p130Cas in ErbB2 breast cancer and supports the hypothesis that p130Cas/ErbB2 interaction can serve as a potential target for the discovery and development of new anticancer agents, that can be used in combination with standard therapy to manage and control Trastuzumab resistance. This evidence concerns the gene ERBB2 and breast carcinoma.